1. Батюшин ММ, Галушкин АА, Пасечник ДГ и др. Клинический случай С1q-нефропатии. Нефрология 2012; 16(3): 117-121
2. Jennette JC, Hipp CG: Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol 1985; 83: 415-420
3. Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis 1985;6:103-10
4. Vizjak A, Ferluga D, Rožič М et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol 2008; 19(11): 2237-2244
5. Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, D'Agati VD: C1q nephropathy: a variant of segmental glomerulosclerosis. Kidney Int 2003; 64: 1232-1240
6. Hisano S, Fukuma Y, Segawa Y et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol 2008;3:1637-1643
7. Добронравов ВА. Гипокомплементемический уртикарный васкулит: введение в клинику и иммунобиологию Нефрология 2011; 15(1): 17-26
8. Emancipator SN. Benign essential hematuria, IgA nephropathy, and Alport syndrome. In: Renal Biopsy Interpretation, eds Silva FG, D’Agati VD, Nadasdy T, Churchill Livingstone, New York, 1996; 147-180
9. Nishida M, Kawakatsu H, Komatsu H et al. Spontaneous improvement in a case of C1q nephropathy. Am J Kidney Dis 2000 May;35(5):E22
10. Castellano G, Melchiorre R, Loverre A et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol 2010;176(4):1648-1659
11. Thurman JM, Renner B. Dynamic control of the complement system by modulated expression of regulatory proteins Lab Invest 2011; 91(1): 4-11
Послать статью по эл. почте 